Caio M Rocha-Lima

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
    C M Rocha Lima
    University of Miami and Sylvester Cancer Center, Miami, FL 33136, USA
    Ann Oncol 15:410-8. 2004
  2. pmc Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida
    Wen Liu-Mares
    Department of Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14th St, CRB 1512, Miami, FL 33136, USA
    BMC Cancer 13:111. 2013
  3. doi request reprint A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors
    Caio M Rocha-Lima
    Department of Medical Oncology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida, USA
    Cancer 118:4262-70. 2012
  4. doi request reprint New directions in the management of advanced pancreatic cancer: a review
    Caio M Rocha-Lima
    University of Miami Miller School of Medicine and Sylvester Cancer Center, Miami, Florida 33136, USA
    Anticancer Drugs 19:435-46. 2008
  5. ncbi request reprint Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902
    C M Rocha-Lima
    University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Ann Oncol 18:331-7. 2007
  6. ncbi request reprint Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    Caio M Rocha Lima
    University of Miami and Sylvester Cancer Center, Miami, FL 33162, USA
    J Clin Oncol 22:3776-83. 2004
  7. ncbi request reprint A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
    Caio M S Rocha Lima
    Department of Medicine, University of Miami Sylvester Cancer Center, Miami, Florida 33136, USA
    Cancer 100:2671-9. 2004
  8. ncbi request reprint Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Am J Clin Oncol 35:446-50. 2012
  9. pmc A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    BMC Cancer 12:199. 2012
  10. doi request reprint Role of combined-modality therapy in the management of locally advanced rectal cancer
    Peter J Hosein
    Division of Hematology Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA
    Clin Colorectal Cancer 7:369-75. 2008

Detail Information

Publications15

  1. ncbi request reprint Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
    C M Rocha Lima
    University of Miami and Sylvester Cancer Center, Miami, FL 33136, USA
    Ann Oncol 15:410-8. 2004
    ..To evaluate the activity and tolerability of gemcitabine plus irinotecan or docetaxel as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC)...
  2. pmc Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida
    Wen Liu-Mares
    Department of Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14th St, CRB 1512, Miami, FL 33136, USA
    BMC Cancer 13:111. 2013
    ..We sought to identify high-risk areas of pancreatic cancer incidence, and determine if clusters of persons diagnosed with pancreatic cancer were more likely to be located near arsenic-contaminated drinking water wells...
  3. doi request reprint A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors
    Caio M Rocha-Lima
    Department of Medical Oncology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida, USA
    Cancer 118:4262-70. 2012
    ..E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids)...
  4. doi request reprint New directions in the management of advanced pancreatic cancer: a review
    Caio M Rocha-Lima
    University of Miami Miller School of Medicine and Sylvester Cancer Center, Miami, Florida 33136, USA
    Anticancer Drugs 19:435-46. 2008
    ..This review focuses on the recent developments in systemic treatment, and discusses how novel agents might be incorporated into future treatment strategies for pancreatic cancer...
  5. ncbi request reprint Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902
    C M Rocha-Lima
    University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Ann Oncol 18:331-7. 2007
    ..This phase II study evaluated the efficacy and safety of the irinotecan/gemcitabine combination in patients with relapsed/refractory small-cell lung cancer (SCLC)...
  6. ncbi request reprint Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    Caio M Rocha Lima
    University of Miami and Sylvester Cancer Center, Miami, FL 33162, USA
    J Clin Oncol 22:3776-83. 2004
    ....
  7. ncbi request reprint A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
    Caio M S Rocha Lima
    Department of Medicine, University of Miami Sylvester Cancer Center, Miami, Florida 33136, USA
    Cancer 100:2671-9. 2004
    ....
  8. ncbi request reprint Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Am J Clin Oncol 35:446-50. 2012
    ..Little progress has been made in the treatment of pancreatic cancer (PC). This study evaluated the clinical activity of gemcitabine, oxaliplatin, and cetuximab (GOC) in patients with locally advanced or metastatic PC...
  9. pmc A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    BMC Cancer 12:199. 2012
    ..We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC)...
  10. doi request reprint Role of combined-modality therapy in the management of locally advanced rectal cancer
    Peter J Hosein
    Division of Hematology Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA
    Clin Colorectal Cancer 7:369-75. 2008
    ..Ongoing trials are testing the integration of newer cytotoxic agents such as capecitabine, oxaliplatin, irinotecan, and biologic agents such as cetuximab and bevacizumab to chemoradiation...
  11. ncbi request reprint EGFR targeting of solid tumors
    Caio M Rocha-Lima
    Department of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA
    Cancer Control 14:295-304. 2007
    ..Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer...
  12. doi request reprint Advanced or metastatic pancreatic cancer: molecular targeted therapies
    Soley Bayraktar
    Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, University of Miami, Miami, FL, USA
    Mt Sinai J Med 77:606-19. 2010
    ..This review describes some of the important developments and targeted agents for pancreatic cancer that have been tested in clinical trials...
  13. pmc Molecular basis and management of gastrointestinal stromal tumors
    Ulas D Bayraktar
    Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, St 3300, Miami, FL 33136, USA
    World J Gastroenterol 16:2726-34. 2010
    ..Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs...
  14. pmc Severe colitis associated with docetaxel use: A report of four cases
    Andres F Carrion
    Andres F Carrion, Peter J Hosein, Eugene M Cooper, Liset Pelaez, Caio M Rocha Lima, Department of Medicine, Division of Gastroenterology, Hematology Oncology, Pathology, University of Miami Miller School of Medicine, Miami, FL 33136, United States
    World J Gastrointest Oncol 2:390-4. 2010
    ..These cases provide some insight into the spectrum and varied clinical presentations of severe colitis associated with taxane-based chemotherapy...
  15. ncbi request reprint Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002
    Antonius A Miller
    Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    J Thorac Oncol 2:645-51. 2007
    ....